Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resmetirom in severe renal impairment
NCT06397872Phase 1Completed
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Mar 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of resmetirom (2 arms), sponsored by Madrigal Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at 8 days, Time to Maximum Plasma Concentration at 8 days and 2 more. Started Mar 2024; status: completed.
02
Drugs
resmetirom
Beyond the preview
Go deeper on NCT06397872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06397872.